A proposed oral treatment for Type 1 diabetes in adults has been rejected in the U.S.
The rejection of what would have been the first oral treatment for Type 1 diabetes in the U.S. is a big setback for Lexicon Pharmaceuticals Inc.
, a small company based in a Houston suburb that currently has one product on the market and losses of nearly $1.5 billion as of Dec. 31. Lexicon is developing the treatment, which is called Zynquista, with French pharmaceutical giant Sanofi.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetesThe U.S. Food and Drug Administration declined to approve a drug developed by Sa...
Consulte Mais informação »
FDA approves the first drug designed to treat postpartum depressionThe FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
Consulte Mais informação »
FDA says cybersecurity vulnerabilities found in some Medtronic devicesThe U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulne...
Consulte Mais informação »
Indonesian airline Garuda is canceling its $6 billion order for 49 Boeing 737 Max jetsBoeing 737 Max planes have been grounded by authorities after two recent fatal crashes.
Consulte Mais informação »
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Consulte Mais informação »
FDA issues warning to two breast implant makers over safety concernsLess than a week before a major hearing on breast implant safety, the FDA issued two warning letters to implant manufacturers, citing their failure to do proper safety studies.
Consulte Mais informação »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Consulte Mais informação »